Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival
Archivum Immunologiae et Therapiae Experimentalis · 2026
DOI: 10.2478/aite-2026-0013 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archivum Immunologiae et Therapiae Experimentalis, 2026. Verfasst von Maria Siemionow und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Graft Rejection, Mesenchymal Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Chimerism-based strategies remain promising for tolerance induction in solid organ and vascularized composite allograft (VCA) transplantation. This study aimed to develop a novel, less toxic chimeric cell therapy to prolong allograft survival and reduce the need for lifelong immunosuppression. Di-chimeric cells (DCC) were created via polyethylene glycol (PEG)-mediated ex vivo fusion of allogeneic hematopoietic stem cells (HSC) and mesenchymal stem cells (MSC) derived from August Copenhagen Irish (ACI) and Lewis rats. Twenty-four fully major histocompatibility complex (MHC)-mismatched groin flap VCAs were transplanted from ACI rat major histocompatibility complex (rat MHC) (RT1 a ) donors to Lewis (RT1 1 ) recipients under a 7-day immunosuppressive protocol of anti-αβTCR antibody and tacrolimus, combined with four different cell therapies of n = 6/group: Group 1, saline control; Group 2, MSC; Group 3, HSC/HSC DCC; and Group 4, HSC/MSC DCC. DCC were delivered via the intraosseous injection. DCC phenotype was confirmed by flow cytometry (FC). Graft rejection was evaluated macroscopically. A single DCC dose significantly prolonged VCA survival, with the best results in Group 4 (94 ± 1.65 days), followed by Group 3 (66 ± 1.24 days), Group 2 (45.5 ± 4.08 days), and Group 1 (38 ± 4.29 days). This study confirmed immunomodulatory and tolerogenic properties of DCC, supporting VCA transplantation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedics, University of Illinois at Chicago, Chicago, IL, USA.
Zitieren
APA
Siemionow, M., Uygur, S. H., Stawarz, K., Chambily, L., Budzynska, K., & Radecka, W. (2026). Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival. Archivum Immunologiae et Therapiae Experimentalis. https://doi.org/10.2478/aite-2026-0013
Vancouver
Siemionow M, Uygur SH, Stawarz K, Chambily L, Budzynska K, Radecka W. Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival. Archivum Immunologiae et Therapiae Experimentalis. 2026. doi:10.2478/aite-2026-0013
BibTeX
@article{Siemionow2026,
author = {Siemionow, Maria and Uygur, Safak Halil and Stawarz, Katarzyna and Chambily, Lucile and Budzynska, Katarzyna and Radecka, Weronika},
title = {Di-Chimeric Cell Therapy Derived From Hematopoietic and Mesenchymal Stem Cells Promotes Immune Tolerance and Extends Vascularized Composite Allograft Survival},
journal = {Archivum Immunologiae et Therapiae Experimentalis},
year = {2026},
doi = {10.2478/aite-2026-0013}
}
EUVIMED